Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%

Ryan Cross

Senior Science Correspondent

Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost entirely eliminated swelling attacks in 10 people with hereditary …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

In­tel­lia plots Phase 3 study and a 2026 FDA sub­mis­sion af­ter CRISPR ther­a­py cuts swelling at­tacks by 98%

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%